Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 16/20 | 0.56 |
| ▸ | MMP13 | P45452 | 15/20 | 0.56 |
| ▸ | MMP2 | P08253 | 4/20 | 0.44 |
| ▸ | MMP9 | P14780 | 4/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28722341 | 0.88 | MMP13 (0.57) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL250645 | 0.86 | MMP1 (0.76) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL28707435 | 0.78 | MMP1 (0.56) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL3874407 | 0.77 | MMP1 (0.76) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL3855639 | 0.75 | MMP1 (0.76) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL27450137 | 0.74 | MMP1 (0.65) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6956661 | 0.72 | MMP1 (0.84) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6994418 | 0.72 | MMP1 (1.00) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6994423 | 0.72 | MMP1 (1.00) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6957079 | 0.70 | MMP1 (0.80) | MMP1MMP13MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072885-A1 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072885-A1 | BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | UGT1A1, CCNA1, UGT1A3 | MMP1 551/4885MMP13 669/4885MMP2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.